Phase 3Active, not recruiting
Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)
- Sponsor
- Vera Therapeutics, Inc. (Industry)
- Enrolment
- 428 enrolled
- Conditions
- IgA Nephropathy; Berger Disease
- Interventions
- Atacicept; Placebo to match Atacicept
- Ages
- adults, older adults
- Registry
- NCT04716231
Full record on ClinicalTrials.gov
From the registry
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Primary outcomes
- Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)
History
Study completion expected
Results first posted
Last registry update
Primary completion
Started
Registered